{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:16:34Z","timestamp":1788790594963,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"DOI":"10.7759\/cureus.97147","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:32:47Z","timestamp":1763469167000},"source":"Crossref","is-referenced-by-count":2,"title":["Effects of Fibroblast Growth Factor 23 (FGF23) on the Cardiovascular System: A Review of Literature"],"prefix":"10.7759","author":[{"given":"Diego Ivan","family":"Diaz-Haaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleasib Alejandro","family":"Espinoza-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Armando","family":"Aguilar-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Megch\u00fan-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gonzalez-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00e9stor Rodolfo","family":"Garc\u00eda-Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-019-0711-y","article-title":"The FGF metabolic axis","volume":"13","author":"Li X","year":"2019","unstructured":"Li X. The FGF metabolic axis. Front Med. 2019, 13:511-30. 10.1007\/s11684-019-0711-y","journal-title":"Front Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021119-034650","article-title":"Regulation and effects of FGF23 in chronic kidney disease","volume":"82","author":"Musgrove J","year":"2020","unstructured":"Musgrove J, Wolf M. Regulation and effects of FGF23 in chronic kidney disease. Annu Rev Physiol. 2020, 82:365-90. 10.1146\/annurev-physiol-021119-034650","journal-title":"Annu Rev Physiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06155-9","article-title":"Structural basis for FGF hormone signalling","volume":"618","author":"Chen L","year":"2023","unstructured":"Chen L, Fu L, Sun J, et al.. Structural basis for FGF hormone signalling. Nature. 2023, 618:862-70. 10.1038\/s41586-023-06155-9","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-021-00703-w","article-title":"Regulation of FGF23: Beyond bone","volume":"19","author":"Simic P","year":"2021","unstructured":"Simic P, Babitt JL. Regulation of FGF23: Beyond bone. Curr Osteoporos Rep. 2021, 19:563-73. 10.1007\/s11914-021-00703-w","journal-title":"Curr Osteoporos Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8821292","article-title":"FGF23: A review of its role in mineral metabolism and renal and cardiovascular disease","volume":"2021","author":"Kurpas A","year":"2021","unstructured":"Kurpas A, Supe\u0142 K, Idzikowska K, Zieli\u0144ska M. FGF23: A review of its role in mineral metabolism and renal and cardiovascular disease. Dis Markers. 2021, 2021:8821292. 10.1155\/2021\/8821292","journal-title":"Dis Markers"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1059179","article-title":"Direct and indirect effects of fibroblast growth factor 23 on the heart","volume":"14","author":"Nakano T","year":"2023","unstructured":"Nakano T, Kishimoto H, Tokumoto M. Direct and indirect effects of fibroblast growth factor 23 on the heart. Front Endocrinol. 2023, 14:1059179. 10.3389\/fendo.2023.1059179","journal-title":"Front Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2016.01.011","article-title":"Bone mineral disorder in chronic kidney disease: Klotho and FGF23; cardiovascular implications. (Article in Spanish)","volume":"36","author":"Salanova Villanueva L","year":"2016","unstructured":"Salanova Villanueva L, S\u00e1nchez Gonz\u00e1lez C, S\u00e1nchez Tomero JA, Aguilera A, Ortega Junco E. Bone mineral disorder in chronic kidney disease: Klotho and FGF23; cardiovascular implications. (Article in Spanish). Nefrologia. 2016, 36:368-75. 10.1016\/j.nefro.2016.01.011","journal-title":"Nefrologia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.13494","article-title":"Regulation of fibroblast growth factor 23 (FGF23) in health and disease","volume":"593","author":"B\u00e4r L","year":"2019","unstructured":"B\u00e4r L, Stournaras C, Lang F, F\u00f6ller M. Regulation of fibroblast growth factor 23 (FGF23) in health and disease. FEBS Lett. 2019, 593:1879-900. 10.1002\/1873-3468.13494","journal-title":"FEBS Lett"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4003","article-title":"IL-1\u03b2 drives production of FGF-23 at the onset of chronic kidney disease in mice","volume":"35","author":"McKnight Q","year":"2020","unstructured":"McKnight Q, Jenkins S, Li X, et al.. IL-1\u03b2 drives production of FGF-23 at the onset of chronic kidney disease in mice. J Bone Miner Res. 2020, 35:1352-62. 10.1002\/jbmr.4003","journal-title":"J Bone Miner Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00278","article-title":"Paracrine effects of FGF23 on the heart","volume":"9","author":"Leifheit-Nestler M","year":"2018","unstructured":"Leifheit-Nestler M, Haffner D. Paracrine effects of FGF23 on the heart. Front Endocrinol (Lausanne). 2018, 9:278. 10.3389\/fendo.2018.00278","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04843-6","article-title":"Fibroblast growth factor 23\u2014Klotho and hypertension: Experimental and clinical mechanisms","volume":"36","author":"Freundlich M","year":"2021","unstructured":"Freundlich M, Gamba G, Rodriguez-Iturbe B. Fibroblast growth factor 23\u2014Klotho and hypertension: Experimental and clinical mechanisms. Pediatr Nephrol. 2021, 36:3007-22. 10.1007\/s00467-020-04843-6","journal-title":"Pediatr Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11110647","article-title":"FGF23 and phosphate-cardiovascular toxins in CKD","volume":"11","author":"Vogt I","year":"2019","unstructured":"Vogt I, Haffner D, Leifheit-Nestler M. FGF23 and phosphate-cardiovascular toxins in CKD. Toxins (Basel). 2019, 11:647. 10.3390\/toxins11110647","journal-title":"Toxins (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11060","article-title":"FGF23 (fibroblast growth factor-23) and incident hypertension in young and middle-aged adults: The CARDIA Study","volume":"72","author":"Akhabue E","year":"2018","unstructured":"Akhabue E, Montag S, Reis JP, et al.. FGF23 (fibroblast growth factor-23) and incident hypertension in young and middle-aged adults: The CARDIA Study. Hypertension. 2018, 72:70-6. 10.1161\/HYPERTENSIONAHA.118.11060","journal-title":"Hypertension"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.14703","article-title":"Fibroblast growth factor 23 and blood pressure in older adults: The health, aging, and body composition study","volume":"76","author":"Drew DA","year":"2020","unstructured":"Drew DA, Katz R, Kritchevsky S, et al.. Fibroblast growth factor 23 and blood pressure in older adults: The health, aging, and body composition study. Hypertension. 2020, 76:236-43. 10.1161\/HYPERTENSIONAHA.120.14703","journal-title":"Hypertension"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201303716","article-title":"FGF23 regulates renal sodium handling and blood pressure","volume":"6","author":"Andrukhova O","year":"2014","unstructured":"Andrukhova O, Slavic S, Smorodchenko A, et al.. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med. 2014, 6:744-59. 10.1002\/emmm.201303716","journal-title":"EMBO Mol Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00777-1","article-title":"Chronic kidney disease\u2014Mineral and bone disorders: Pathogenesis and management","volume":"108","author":"Cannata-And\u00eda JB","year":"2021","unstructured":"Cannata-And\u00eda JB, Mart\u00edn-Carro B, Mart\u00edn-V\u00edrgala J, Rodr\u00edguez-Carrio J, Bande-Fern\u00e1ndez JJ, Alonso-Montes C, Carrillo-L\u00f3pez N. Chronic kidney disease\u2014Mineral and bone disorders: Pathogenesis and management. Calcif Tissue Int. 2021, 108:410-22. 10.1007\/s00223-020-00777-1","journal-title":"Calcif Tissue Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1530\/JME-20-0121","article-title":"Extracellular phosphate sensing in mammals: What do we know?","volume":"65","author":"Beck L","year":"2020","unstructured":"Beck L, Beck-Cormier S. Extracellular phosphate sensing in mammals: What do we know?. J Mol Endocrinol. 2020, 65:R53-63. 10.1530\/JME-20-0121","journal-title":"J Mol Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000294","article-title":"FGF-23 and cardiovascular disease: Review of literature","volume":"23","author":"Batra J","year":"2016","unstructured":"Batra J, Buttar RS, Kaur P, Kreimerman J, Melamed ML. FGF-23 and cardiovascular disease: Review of literature. Curr Opin Endocrinol Diabetes Obes. 2016, 23:423-9. 10.1097\/MED.0000000000000294","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00560","article-title":"Klotho, aging, and the failing kidney","volume":"11","author":"Buchanan S","year":"2020","unstructured":"Buchanan S, Combet E, Stenvinkel P, Shiels PG. Klotho, aging, and the failing kidney. Front Endocrinol (Lausanne). 2020, 11:560. 10.3389\/fendo.2020.00560","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133967","article-title":"Associations of intact and C-terminal FGF23 with inflammatory markers in older patients affected by advanced chronic kidney disease","volume":"13","author":"Abinti M","year":"2024","unstructured":"Abinti M, Vettoretti S, Caldiroli L, et al.. Associations of intact and C-terminal FGF23 with inflammatory markers in older patients affected by advanced chronic kidney disease. J Clin Med. 2024, 13:3967. 10.3390\/jcm13133967","journal-title":"J Clin Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s40348-021-00123-x","article-title":"How FGF23 shapes multiple organs in chronic kidney disease","volume":"8","author":"Leifheit-Nestler M","year":"2021","unstructured":"Leifheit-Nestler M, Haffner D. How FGF23 shapes multiple organs in chronic kidney disease. Mol Cell Pediatr. 2021, 8:12. 10.1186\/s40348-021-00123-x","journal-title":"Mol Cell Pediatr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01160308","article-title":"Vitamin D in health and disease","volume":"3","author":"Heaney RP","year":"2008","unstructured":"Heaney RP. Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008, 3:1535-41. 10.2215\/CJN.01160308","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5414\/cnp64288","article-title":"Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis","volume":"64","author":"Mucsi I","year":"2005","unstructured":"Mucsi I, Alm\u00e1si C, De\u00e1k G, et al.. Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol. 2005, 64:288-94. 10.5414\/cnp64288","journal-title":"Clin Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092736","article-title":"The anti-inflammatory effects of vitamin D in tumorigenesis","volume":"19","author":"Liu W","year":"2018","unstructured":"Liu W, Zhang L, Xu HJ, Li Y, Hu CM, Yang JY, Sun MY. The anti-inflammatory effects of vitamin D in tumorigenesis. Int J Mol Sci. 2018, 19:2736. 10.3390\/ijms19092736","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2016.11.009","article-title":"Contribution of fibroblast growth factor 23 to Framingham risk score for identifying subclinical atherosclerosis in Chinese men","volume":"27","author":"Hu X","year":"2017","unstructured":"Hu X, Ma X, Luo Y, et al.. Contribution of fibroblast growth factor 23 to Framingham risk score for identifying subclinical atherosclerosis in Chinese men. Nutr Metab Cardiovasc Dis. 2017, 27:147-53. 10.1016\/j.numecd.2016.11.009","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00311","article-title":"The heart and kidney: Abnormal phosphate homeostasis is associated with atherosclerosis","volume":"3","author":"Holden RM","year":"2018","unstructured":"Holden RM, H\u00e9tu MF, Li TY, et al.. The heart and kidney: Abnormal phosphate homeostasis is associated with atherosclerosis. J Endocr Soc. 2018, 3:159-70. 10.1210\/js.2018-00311","journal-title":"J Endocr Soc"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02205-2","article-title":"Relationships of serum FGF23 and \u03b1-klotho with atherosclerosis in patients with type 2 diabetes mellitus","volume":"23","author":"Bi J","year":"2024","unstructured":"Bi J, Zheng M, Li K, Sun S, Zhang Z, Yan N, Li X. Relationships of serum FGF23 and \u03b1-klotho with atherosclerosis in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2024, 23:128. 10.1186\/s12933-024-02205-2","journal-title":"Cardiovasc Diabetol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.12.008","article-title":"Fibroblast growth factor 23 predicts carotid atherosclerosis in individuals without kidney disease. The CORDIOPREV study","volume":"74","author":"Rodr\u00edguez-Ortiz ME","year":"2020","unstructured":"Rodr\u00edguez-Ortiz ME, Alcal\u00e1-D\u00edaz JF, Canalejo A, et al.. Fibroblast growth factor 23 predicts carotid atherosclerosis in individuals without kidney disease. The CORDIOPREV study. Eur J Intern Med. 2020, 74:79-85. 10.1016\/j.ejim.2019.12.008","journal-title":"Eur J Intern Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05080422","article-title":"Fibroblast growth factor-23 and risk of cardiovascular diseases: A Mendelian Randomization Study","volume":"18","author":"Donovan K","year":"2023","unstructured":"Donovan K, Herrington WG, Par\u00e9 G, et al.. Fibroblast growth factor-23 and risk of cardiovascular diseases: A Mendelian Randomization Study. Clin J Am Soc Nephrol. 2023, 18:17-27. 10.2215\/CJN.05080422","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00264.2014","article-title":"FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability","volume":"307","author":"Silswal N","year":"2014","unstructured":"Silswal N, Touchberry CD, Daniel DR, et al.. FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab. 2014, 307:E426-36. 10.1152\/ajpendo.00264.2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-016-1858-x","article-title":"Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells","volume":"468","author":"Richter B","year":"2016","unstructured":"Richter B, Haller J, Haffner D, Leifheit-Nestler M. Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells. Pflugers Arch. 2016, 468:1621-35. 10.1007\/s00424-016-1858-x","journal-title":"Pflugers Arch"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59820","article-title":"Impact of elevated fibroblast growth factor 23 (FGF23) on the cardiovascular system: A comprehensive systematic literature review","volume":"16","author":"Amaravadi KS","year":"2024","unstructured":"Amaravadi KS, Nalisetty P, Vadlamani N, Ibrahimli S, Khan FA, Castillo JA, Penumetcha SS. Impact of elevated fibroblast growth factor 23 (FGF23) on the cardiovascular system: A comprehensive systematic literature review. Cureus. 2024, 16:e59820. 10.7759\/cureus.59820","journal-title":"Cureus"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul C","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, et al.. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011, 121:4393-408. 10.1172\/JCI46122","journal-title":"J Clin Invest"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.01.024","article-title":"Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease","volume":"107","author":"Fuchs MA","year":"2025","unstructured":"Fuchs MA, Burke EJ, Latic N, et al.. Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease. Kidney Int. 2025, 107:852-68. 10.1016\/j.kint.2025.01.024","journal-title":"Kidney Int"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.702719","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease\u2014A pediatric perspective","volume":"9","author":"Grund A","year":"2021","unstructured":"Grund A, Sinha MD, Haffner D, Leifheit-Nestler M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease\u2014A pediatric perspective. Front Pediatr. 2021, 9:702719. 10.3389\/fped.2021.702719","journal-title":"Front Pediatr"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Guti\u00e9rrez OM","year":"2009","unstructured":"Guti\u00e9rrez OM, Januzzi JL, Isakova T, et al.. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009, 119:2545-52. 10.1161\/CIRCULATIONAHA.108.844506","journal-title":"Circulation"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1242108","article-title":"Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction\u2014a substudy of the DAPA-VO(2) study","volume":"10","author":"Mora-Fern\u00e1ndez C","year":"2023","unstructured":"Mora-Fern\u00e1ndez C, P\u00e9rez A, Mollar A, et al.. Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction\u2014a substudy of the DAPA-VO(2) study. Front Cardiovasc Med. 2023, 10:1242108. 10.3389\/fcvm.2023.1242108","journal-title":"Front Cardiovasc Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100723","article-title":"Fibroblast growth factor 23 and risk of heart failure subtype: The CRIC (Chronic Renal Insufficiency Cohort) Study","volume":"5","author":"Leidner AS","year":"2023","unstructured":"Leidner AS, Cai X, Zelnick LR, et al.. Fibroblast growth factor 23 and risk of heart failure subtype: The CRIC (Chronic Renal Insufficiency Cohort) Study. Kidney Med. 2023, 5:100723. 10.1016\/j.xkme.2023.100723","journal-title":"Kidney Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42558-4","article-title":"FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF","volume":"13","author":"Benes J","year":"2023","unstructured":"Benes J, Kroupova K, Kotrc M, et al.. FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF. Sci Rep. 2023, 13:16004. 10.1038\/s41598-023-42558-4","journal-title":"Sci Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-023-03441-2","article-title":"Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction","volume":"23","author":"Vergaro G","year":"2023","unstructured":"Vergaro G, Del Franco A, Aimo A, et al.. Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction. BMC Cardiovasc Disord. 2023, 23:433. 10.1186\/s12872-023-03441-2","journal-title":"BMC Cardiovasc Disord"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28548","article-title":"FGF23 regulates atrial fibrosis in atrial fibrillation by mediating the STAT3 and SMAD3 pathways","volume":"234","author":"Dong Q","year":"2019","unstructured":"Dong Q, Li S, Wang W, et al.. FGF23 regulates atrial fibrosis in atrial fibrillation by mediating the STAT3 and SMAD3 pathways. J Cell Physiol. 2019, 234:19502-10. 10.1002\/jcp.28548","journal-title":"J Cell Physiol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s12055-021-01328-5","article-title":"Role of fibroblast growth factor-23 (FGF-23) in the prediction of postoperative atrial fibrillation after coronary artery bypass surgery","volume":"38","author":"Jadhav KP","year":"2022","unstructured":"Jadhav KP, Pai PG, Nair I, Krishnan S, Varma PK. Role of fibroblast growth factor-23 (FGF-23) in the prediction of postoperative atrial fibrillation after coronary artery bypass surgery. Indian J Thorac Cardiovasc Surg. 2022, 38:251-61. 10.1007\/s12055-021-01328-5","journal-title":"Indian J Thorac Cardiovasc Surg"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.899667","article-title":"Relationship between serum growth differentiation factor 15, fibroblast growth factor-23 and risk of atrial fibrillation: A systematic review and meta-analysis","volume":"9","author":"Tan Z","year":"2022","unstructured":"Tan Z, Song T, Huang S, et al.. Relationship between serum growth differentiation factor 15, fibroblast growth factor-23 and risk of atrial fibrillation: A systematic review and meta-analysis. Front Cardiovasc Med. 2022, 9:899667. 10.3389\/fcvm.2022.899667","journal-title":"Front Cardiovasc Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.15190\/d.2019.10","article-title":"Cardiac FGF23: A new player in myocardial infarction","volume":"7","author":"Schumacher D","year":"2019","unstructured":"Schumacher D, Schuh A. Cardiac FGF23: A new player in myocardial infarction. Discoveries (Craiova). 2019, 7:e97. 10.15190\/d.2019.10","journal-title":"Discoveries (Craiova)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03644-9","article-title":"Inflammatory plasma proteins predict short-term mortality in patients with an acute myocardial infarction","volume":"20","author":"Schmitz T","year":"2022","unstructured":"Schmitz T, Harmel E, Heier M, Peters A, Linseisen J, Meisinger C. Inflammatory plasma proteins predict short-term mortality in patients with an acute myocardial infarction. J Transl Med. 2022, 20:457. 10.1186\/s12967-022-03644-9","journal-title":"J Transl Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1173281","article-title":"Baseline fibroblast growth factor 23 is associated with long-term mortality in ST-elevation myocardial infarction-results from the augsburg myocardial infarction registry","volume":"10","author":"Schmitz T","year":"2023","unstructured":"Schmitz T, Wein B, Heier M, Peters A, Meisinger C, Linseisen J. Baseline fibroblast growth factor 23 is associated with long-term mortality in ST-elevation myocardial infarction-results from the augsburg myocardial infarction registry. Front Cardiovasc Med. 2023, 10:1173281. 10.3389\/fcvm.2023.1173281","journal-title":"Front Cardiovasc Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.632260","article-title":"An overview of FGF-23 as a novel candidate biomarker of cardiovascular risk","volume":"12","author":"V\u00e1zquez-S\u00e1nchez S","year":"2021","unstructured":"V\u00e1zquez-S\u00e1nchez S, Poveda J, Navarro-Garc\u00eda JA, Gonz\u00e1lez-Lafuente L, Rodr\u00edguez-S\u00e1nchez E, Ruilope LM, Ruiz-Hurtado G. An overview of FGF-23 as a novel candidate biomarker of cardiovascular risk. Front Physiol. 2021, 12:632260. 10.3389\/fphys.2021.632260","journal-title":"Front Physiol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184634","article-title":"FGF23-mediated activation of local RAAS promotes cardiac hypertrophy and fibrosis","volume":"20","author":"B\u00f6ckmann I","year":"2019","unstructured":"B\u00f6ckmann I, Lischka J, Richter B, et al.. FGF23-mediated activation of local RAAS promotes cardiac hypertrophy and fibrosis. Int J Mol Sci. 2019, 20:4634. 10.3390\/ijms20184634","journal-title":"Int J Mol Sci"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.4103\/cjop.CJOP-D-23-00048","article-title":"Paricalcitol improved cardiac hypertrophy and fibrosis through upregulation of fibroblast growth factor-23 and downregulation of transforming growth factor-beta in a rat model of isoproterenol-induced cardiomyopathy","volume":"66","author":"Wu CJ","year":"2023","unstructured":"Wu CJ, Li YH, Chen HH. Paricalcitol improved cardiac hypertrophy and fibrosis through upregulation of fibroblast growth factor-23 and downregulation of transforming growth factor-beta in a rat model of isoproterenol-induced cardiomyopathy. Chin J Physiol. 2023, 66:306-12. 10.4103\/cjop.CJOP-D-23-00048","journal-title":"Chin J Physiol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez OM","year":"2008","unstructured":"Guti\u00e9rrez OM, Mannstadt M, Isakova T, et al.. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008, 359:584-92. 10.1056\/NEJMoa0706130","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017070772","article-title":"Longitudinal FGF23 trajectories and mortality in patients with CKD","volume":"29","author":"Isakova T","year":"2018","unstructured":"Isakova T, Cai X, Lee J, et al.. Longitudinal FGF23 trajectories and mortality in patients with CKD. J Am Soc Nephrol. 2018, 29:579-90. 10.1681\/ASN.2017070772","journal-title":"J Am Soc Nephrol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Kendrick J","year":"2011","unstructured":"Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol. 2011, 22:1913-22. 10.1681\/ASN.2010121224","journal-title":"J Am Soc Nephrol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010080894","article-title":"Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality","volume":"22","author":"Wolf M","year":"2011","unstructured":"Wolf M, Molnar MZ, Amaral AP, et al.. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol. 2011, 22:956-66. 10.1681\/ASN.2010080894","journal-title":"J Am Soc Nephrol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.03.040","article-title":"Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study)","volume":"60","author":"Ix JH","year":"2012","unstructured":"Ix JH, Katz R, Kestenbaum BR, et al.. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol. 2012, 60:200-7. 10.1016\/j.jacc.2012.03.040","journal-title":"J Am Coll Cardiol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00033-4","article-title":"Clinical management of the uraemic syndrome in chronic kidney disease","volume":"4","author":"Vanholder R","year":"2016","unstructured":"Vanholder R, Fouque D, Glorieux G, et al.. Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diabetes Endocrinol. 2016, 4:360-73. 10.1016\/S2213-8587(16)00033-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2013.09.001","article-title":"Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease","volume":"24","author":"Adema AY","year":"2014","unstructured":"Adema AY, de Borst MH, Ter Wee PM, Vervloet MG. Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease. J Ren Nutr. 2014, 24:143-50. 10.1053\/j.jrn.2013.09.001","journal-title":"J Ren Nutr"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1159\/000319650","article-title":"Fibroblast growth factor 23 in hemodialysis patients: Effects of phosphate binder, calcitriol and calcium concentration in the dialysate","volume":"117","author":"Cancela AL","year":"2010","unstructured":"Cancela AL, Oliveira RB, Graciolli FG, et al.. Fibroblast growth factor 23 in hemodialysis patients: Effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract. 2010, 117:c74-82. 10.1159\/000319650","journal-title":"Nephron Clin Pract"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1530\/JME-20-0089","article-title":"FGF23-related hypophosphatemic rickets\/osteomalacia: Diagnosis and new treatment","volume":"66","author":"Fukumoto S","year":"2021","unstructured":"Fukumoto S. FGF23-related hypophosphatemic rickets\/osteomalacia: Diagnosis and new treatment. J Mol Endocrinol. 2021, 66:R57-65. 10.1530\/JME-20-0089","journal-title":"J Mol Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/432743-effects-of-fibroblast-growth-factor-23-fgf23-on-the-cardiovascular-system-a-review-of-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:32:48Z","timestamp":1763469168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/432743-effects-of-fibroblast-growth-factor-23-fgf23-on-the-cardiovascular-system-a-review-of-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":58,"URL":"https:\/\/doi.org\/10.7759\/cureus.97147","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}